Verona Pharma PLC

More Details of Verona Pharma PLC Company

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Company Info

Company codeVRNA

Company nameVerona Pharma PLC

IPO dateMar 30, 2005

Founded at2005

CEODr. David S. Zaccardelli

Number of employees209

Security typeDepository Receipt

Fiscal year-endMar 30

AddressRiverside

CityLONDON

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited Kingdom

Postal codeSE1 2RE

Phone442032834200

Websitehttps://www.veronapharma.com/

Company codeVRNA

IPO dateMar 30, 2005

Founded at2005

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. David S. Zaccardelli

President, Chief Executive Officer, Executive Director

791.27K

-49.86%

Mr. Mark W. Hahn, CPA

Chief Financial Officer

677.38K

-53.74%

Ms. Claire Louise Poll

General Counsel

541.81K

--

Mr. Vikas Sinha, CPA

Non-Executive Independent Director

74.44K

--

Dr. Mahendra G. Shah, Ph.D.

Non-Executive Independent Director

73.08K

+700.00%

Ms. Lisa Deschamps

Non-Executive Independent Director

70.32K

+700.00%

Mr. Michael Austwick

Non-Executive Director

--

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

--

Ms. Christina Ackermann

Non-Executive Director

--

Dr. Martin William Edwards, M.D.

Non-Executive Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. David S. Zaccardelli

President, Chief Executive Officer, Executive Director

791.27K

-49.86%

Mr. Mark W. Hahn, CPA

Chief Financial Officer

677.38K

-53.74%

Ms. Claire Louise Poll

General Counsel

541.81K

--

Mr. Vikas Sinha, CPA

Non-Executive Independent Director

74.44K

--

Dr. Mahendra G. Shah, Ph.D.

Non-Executive Independent Director

73.08K

+700.00%

Ms. Lisa Deschamps

Non-Executive Independent Director

70.32K

+700.00%

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholder

Update time: Sun, May 18

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Perceptive Advisors LLC

7.71%

Janus Henderson Investors

6.48%

Darwin Global Management Ltd

4.61%

Frazier Life Sciences Management, L.P.

4.06%

Ali (Behbahani)

3.75%

Other

73.39%

Shareholder Statistics

Shareholder

Proportion

Perceptive Advisors LLC

7.71%

Janus Henderson Investors

6.48%

Darwin Global Management Ltd

4.61%

Frazier Life Sciences Management, L.P.

4.06%

Ali (Behbahani)

3.75%

Other

73.39%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

25.32%

Hedge Fund

23.51%

Investment Advisor

16.16%

Private Equity

12.03%

Individual Investor

10.87%

Venture Capital

5.02%

Research Firm

3.63%

Family Office

1.18%

Bank and Trust

0.26%

Other

2.03%

Institutional Shareholding

Update time: Tue, Mar 4

Chg %

Shares Held

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

362

99.25M

116.64%

+16.32M

2024Q4

326

71.46M

84.46%

-16.29M

2024Q3

290

72.06M

88.66%

-13.37M

2024Q2

265

71.81M

88.57%

-10.49M

2024Q1

244

72.12M

89.24%

-7.07M

2023Q4

230

69.67M

87.15%

-7.79M

2023Q3

210

67.04M

84.35%

-7.14M

2023Q2

205

65.57M

82.53%

-8.85M

2023Q1

188

68.22M

86.63%

-3.18M

2022Q4

162

65.88M

87.36%

-542.66K

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Perceptive Advisors LLC

6.39M

7.52%

+76.17K

+1.21%

Dec 31, 2024

Janus Henderson Investors

1.67M

1.96%

+624.37K

+59.87%

Dec 31, 2024

Frazier Life Sciences Management, L.P.

3.38M

3.98%

--

Dec 31, 2024

Ali (Behbahani)

3.19M

3.76%

+3.19M

--

Jan 16, 2025

Eventide Asset Management, LLC

3.13M

3.69%

+706.28K

+29.11%

Dec 31, 2024

RTW Investments L.P.

1.82M

2.14%

+1.82M

--

Dec 31, 2024

New Enterprise Associates (NEA)

4.08M

4.81%

-1.50M

-26.86%

Jan 16, 2025

Summit Partners Public Asset Management, LLC

1.90M

2.24%

+1.90M

--

Dec 31, 2024

Wellington Management Company, LLP

3.03M

3.56%

+1.15M

+61.03%

Dec 31, 2024

Related ETFs

Update time: Tue, May 6

Name

Proportion

AdvisorShares Dorsey Wright ADR ETF

6.2%

ALPS Medical Breakthroughs ETF

4.06%

First Trust IPOX Europe Equity Opportunities ETF

1.46%

Invesco Nasdaq Biotechnology ETF

0.52%

ProShares Ultra Nasdaq Biotechnology

0.5%

iShares Biotechnology ETF

0.3%

Goldman Sachs Innovate Equity ETF

0.14%

Eventide US Market ETF

0.11%

Fidelity Nasdaq Composite Index ETF

0.01%

First Trust Long/Short Equity ETF

0%

AdvisorShares Dorsey Wright ADR ETF

Proportion6.2%

ALPS Medical Breakthroughs ETF

Proportion4.06%

First Trust IPOX Europe Equity Opportunities ETF

Proportion1.46%

Invesco Nasdaq Biotechnology ETF

Proportion0.52%

ProShares Ultra Nasdaq Biotechnology

Proportion0.5%

iShares Biotechnology ETF

Proportion0.3%

Goldman Sachs Innovate Equity ETF

Proportion0.14%

Eventide US Market ETF

Proportion0.11%

Fidelity Nasdaq Composite Index ETF

Proportion0.01%

First Trust Long/Short Equity ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

81.200USD

Verona Pharma PLC

81.200

Overview

Company